Sign up


Match Document Document Title
6084071 Human L105 polypeptides and polynucleotides encoding same  
A chemokine, human L105, is disclosed.
6083534 Pharmaceutical compositions for controlled release of soluble receptors  
A controlled release pharmaceutical composition includes a biocompatible polymeric material, preferably polyethylene-vinyl acetate or poly(lactic-glucolic acid), having incorporated therein a...
6083906 Method of regulating nitric oxide production or arthritis with soluble IL-17 receptor  
Methods for regulating levels of nitric oxide are disclosed. The methods utilize IL-17 receptors, which may be used in conjunction with inhibitor of IL-1 and/or TNF.
6083503 Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection  
A method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders, and graft rejection is provided, comprising inducing the death by apoptosis of a subpopulation of T...
RE36755 DNA encoding tumor necrosis factor-α and -β receptors  
Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
6080398 Truncated gro and KC chemokines having enhanced bioactivity  
The present invention provides method of increasing the biological activity of KC, gro-α, gro-β, and gro-γ proteins, truncated and modified proteins characterized by having biological activity at...
6077519 Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients  
Methods are provided for eluting peptides that are bound to major histocompatibility complex ("MHC") molecules expressed on the cell surfaces of viable cells that have at least one MHC-peptide...
6074635 T cell activation  
Methods for activating T cells in the absence of antigen, and compositions for effecting the same, are described.
6074639 Ex vivo expansion of hematopoietic cells using interleukin-3 (IL-3) variant fusion proteins  
The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF),...
6066318 Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors  
Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional...
6063372 Uses of mammalian CTLA-8 and related reagents  
Compositions and methods for using CTLA-8 to treat an abnormal physiological condition in an individual. The methods comprise administering a therapeutically effective amount of CTLA-8 alone, or in...
6063757 Wound treatment method with nerve growth factor  
A method is provided for healing chronic wounds in a subject, particularly wounds which exhibit poor vascularization and sensory loss. The treatment method involves administering a therapeutically...
6063373 Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor  
An improved method for the prevention of the inactivation of natural killer (NK) cells and the enhanced activation of NK cells in the presence of monocytes using a combination of a natural killer...
6057133 Multivariant human IL-3 fusion proteins and their recombinant production  
The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF),...
6048971 Recombinant human erythropoietin mutants  
DNA encoding modified, secretable erythropoietin proteins whose ability to regulate the growth and differentiation of red blood cell progenitors are different from the wildtype recombinant...
6048837 OB polypeptides as modulators of body weight  
The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of body weight, and...
6042826 Method for inducing apoptosis of primary central nervous system B cell lymphomas  
A method for treating a primary central nervous system lymphoma in an individual relates to administering intrathecally or intralesionally a therapeutically effective amount of a Fas-cross-linking...
6043344 Human CTLA-8 and uses of CTLA-8-related proteins  
Polynucleotides encoding human CTLA-8 and related proteins are disclosed. Human CTLA-8 proteins and methods for their production are also disclosed. Methods of treatment using human CTLA-8...
6042821 Method of treating sepsis with chemokines  
The invention relates to the method of preventing and treating sepsis using chemokines selected from mature or modified KC [SEQ ID NO: 1], groα [SEQ ID NO:2], groβ [SEQ ID NO: 3] or groγ [SEQ ID NO...
6030812 Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors  
The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins,...
6028050 Method for increasing platelets by administering soluble interleukin-6 receptor  
A platelet-increasing preparation which comprises an effective amount of an interleukin-6 receptor and a pharmaceutically acceptable excipient. Preferably the preparation further comprises...
6027720 G-CSF conjugate  
Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least...
6025325 Pegylated obese (ob) protein compositions  
Polyethylene and polypropylene protein conjugates which modulate body weight of animals and humans for the treatment, prevention and control of obesity and associated diseases or conditions, and...
6025324 Pegylated obese (ob) protein compositions  
Polyethylene and polypropylene protein conjugates which modulate body weight of ani is and humans for the treatment, prevention and control obesity and associated diseases or conditions, and the...
6022535 Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors  
The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins,...
6020323 Compositions and methods for regulation of active TNF-α  
Substances comprising disaccharides and substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, and methods of using same, are disclosed for the...
6019965 Methods for treatment of pulmonary disease using GM-CSF  
Methods of treatment of pulmonary disease, e.g., alveolar proteinosis, by treating a subject with an effective amount of GM-CSF.
6017544 Composition comprising immunogenic stress protein-peptide complexes against cancer and a cytokine  
Disclosed is a method for inhibiting the proliferation of a tumor in a mammal. The method involves the steps of (a) isolating a stress protein-peptide complex from tumor cells previously removed...
6017540 Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes  
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
6017876 Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity  
The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific...
6015883 Rantes homolog from prostate  
The present invention provides a polynucleotide (PTEC) isolated from a prostate cDNA library which identifies and encodes a novel human rantes homolog PTEC (prostate expressed chemokine). The...
6015552 Use of nerve growth factor-2 (NGF-2) /neurotrophin-3 (NT-3) to promote leukocyte proliferation  
Human Nerve Growth Factor-2 (NGF-2, also known as Neurotrophin-3 or NT-3) has been found to promote the proliferation of peripheral blood leukocytes. The invention provides methods using hNGF-2...
6013252 Method promoting conception by administering IL-8 or MCAF  
Leukocyte chemotactic factors such as interleukin-8 and MCAF, and inductive substances therefor were revealed to have proconceptive activities. These activities include promoting ovum growth and...
6008188 Cytokine potentiator and pharmaceutical formulation for cytokine administration  
A cytokine activity enhancer comprising an ethanolamine derivative of the following general formula (I) or a salt thereof, or comprising it along with cytokine or a cytokine production promoter;...
6004548 Analogs of pluripotent granulocyte colony-stimulating factor  
Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte...
6001606 Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby  
There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3...
6001806 Interferon stimulating protein and uses thereof  
This invention relates to the use of the baculovirus glycoprotein, Interferon Stimulating Protein (ISP) (also known as gp67, gp64 EFP, or gp64), or the gene sequence encoding ISP, to stimulate...
6001803 Composition of c-kit ligand, GM-CSF, and TNF-α and method of use  
A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a...
6001649 Chemokine NC28 (monocyte chemotactic protein-3, MCP-3) polypeptides and their recombinant production  
A new chemotactic cytokine, NC28 or Monocyte Chemotactic Protein-3 (MCP-3), is provided. Fragments of the cytokine comprising its 13 C-terminal amino acids also exhibit chemotactic activity. The...
5997857 Co-administration of interleukin-3 mutants with colony stimulating factors  
The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with other colony stimulating factors (CSF), cytokines, lymphokines,...
5997860 Ex-vivo expansion of stem cells using combinations of interleukin-3 (IL-3) variants and other cytokines  
The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines,...
5998378 Compositions for the inhibition of TNF hormone formation and uses thereof  
Compounds having proteolytic inhibitory activity useful for treating diseases, particularly as applied to the treatment of sepsis, AIDS or autoimmune diseases, resulting from a decrease in the...
5998370 Agents for the prevention and/or treatment of radiation-induced disorders by administrating TCF-II  
The use of Tumor Cytotoxic Factor-II (TCF-II) enables the prevention and/or treatment of radiation-induced disorders.
5993810 Method of softening or ripening the cervix of a female mammal using collagenase  
The present invention relates to the use of collagenase and/or one more substances which stimulate the production of naturally occurring collagenase in the cervix to induce labor in a female...
5993798 Oncoinhibin and methods of pharmaceutical use  
The present invention provides a novel human cytokine termed Oncoinhibin. The protein Oncoinhibin is secreted by human erythroblastoid cells, has a molecular weight of approximately 28 kDa and...
5989538 Mpl ligand analogs  
Mpl ligand analogs having one or more changed glycosylation sites as compared to a naturally occurring mpl ligand sequence of a corresponding number of amino acids are disclosed. The invention also...
5989537 Methods for stimulating granulocyte/macrophage lineage using thrombopoietin  
Methods for stimulating granulocyte/macrophage lineage cells using thrombopoiet in are provided. The methods provided may be used to stimulate granulocyte/macrophage progenitors and neutrophils in...
5985261 Use of thioredoxin-like molecules for induction of MnSOD to treat oxidative damage  
A method to increase cellular MnSOD production in an animal to treat oxidative damage by administering a protein having a thioredoxin active-site in reduced state. A composition and a method to...
5985263 Substantially pure histidine-linked protein polymer conjugates  
Substantially pure histidine-linked protein-polymer conjugates and processes for their preparation are disclosed. The processes include contacting a protein with an activated polymer under...
5985613 Use of an "immunodeficiency-virus suppressing lymphokine (ISL) "to inhibit the replication of viruses, in particular of retroviruses  
An isolated polypeptide which inhibits the replication of retroviruses in peripheral blood lymphocytes and i) is encoded by the DNA sequence shown in SEQ ID NO: 1 or complementary sequences; or ii)...